Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 6 of 6 descriptions
| No. | Drug (Description in trials) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | Disease ID | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Anti-von Willebrand Factor Nanobody, Caplacizumab | [2] Caplacizumab Caplacizumab,Von Willebrand factor human | [1] Caplacizumab
Caplacizumab
💬1. Anti-von Willebrand Factor Nanobody, Caplacizumab
| [1] VWF VWF 💬1. Anti-von Willebrand Factor Nanobody, Caplacizumab
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | [1] 64 64 💬1. Anti-von Willebrand Factor Nanobody, Caplacizumab
| ||||||||||||
| 2 | Anti-von Willebrand Factor Nanobody, INN = Caplacizumab | [2] Caplacizumab Caplacizumab,Von Willebrand factor human | [1] Caplacizumab
Caplacizumab
💬2. Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
| [1] VWF VWF 💬2. Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | [1] 64 64 💬2. Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
| ||||||||||||
| 3 | CAPLACIZUMAB | [1] Caplacizumab Caplacizumab | [1] Caplacizumab
Caplacizumab
💬3. CAPLACIZUMAB
| [1] VWF VWF 💬3. CAPLACIZUMAB
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | [1] 64 64 💬3. CAPLACIZUMAB
| ||||||||||||
| 4 | Caplacizumab (ALX-0081) | [1] Caplacizumab Caplacizumab | [1] Caplacizumab
Caplacizumab
💬4. Caplacizumab (ALX-0081)
| [1] VWF VWF 💬4. Caplacizumab (ALX-0081)
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | [1] 64 64 💬4. Caplacizumab (ALX-0081)
| ||||||||||||
| 5 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | [2] Caplacizumab Caplacizumab,Von Willebrand factor human | [1] Caplacizumab
Caplacizumab
💬5. Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
| [1] VWF VWF 💬5. Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | [1] 64 64 💬5. Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
| ||||||||||||
| 6 | Caplacizumab (an anti-von Willebrand Factor Nanobody) | [2] Caplacizumab Caplacizumab,Von Willebrand factor human | [1] Caplacizumab
Caplacizumab
💬6. Caplacizumab (an anti-von Willebrand Factor Nanobody)
| [1] VWF VWF 💬6. Caplacizumab (an anti-von Willebrand Factor Nanobody)
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | [1] 64 64 💬6. Caplacizumab (an anti-von Willebrand Factor Nanobody)
|